FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

AXIM® Biotechnologies Clears Another Hurdle in Development of MS Treatment






















AXIM® Biotechnologies is moving forward with the development of MedChew Rx® pharmaceutical chewing gum products, which are intended as a treatment of multiple sclerosis (MS) symptoms.


The company’s product development partner Quay Pharmaceuticals Ltd. has obtained the necessary licenses from the British government to import the controlled drugs needed for the development of AXIM’s cannabinoid-based pharmaceuticals.

AXIM® and its partners import cannabis strains from the Dutch Government’s Office of Medicinal Cannabis with the specific cannabinoid levels to create products like MedChew Rx®. They then use AXIM®’s patented methods to extract the cannabis oil and purify it into 99 percent pure pharmaceutical-grade cannabinoids.

Using AXIM’s proprietary intellectual properties, they then develop and produce cannabinoid-containing chewing gum products like MedChew Rx®, specially formulated for specific indications.  

Once developed, the cannabinoid-based chewing gum products will be placed into clinical trials to prove safety and efficacy, with the end goal of gaining FDA and equivalent international  approval as prescription medications.

Formulated with 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC), MedChew Rx® is currently being developed as a pharmaceutical drug to treat pain and spasticity associated with MS.

According to the National Multiple Sclerosis Society, “MS is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body.”

The causes of MS are still unknown; however, scientists believe the disease is triggered by environmental factors in a person genetically predisposed to respond. Most people with MS are diagnosed between the ages of 20 and 50, but the progress, severity, and specific symptoms of MS in any one person cannot yet be predicted. The average person in the United States has about a one in 750 chance of developing MS in their lifetime.

The value of the MS treatment market is estimated to reach nearly $25 billion by 2024, according to a report by Grand View Research, Inc. This increase is linked to both a development of new, more effective treatment options, as well as an overall increase of MS diagnosis. It is estimated that 2.3 million people are living with multiple sclerosis worldwide.

Now that AXIM® Biotechnologies has obtained their license from the British government to import controlled substances, they are able to move beyond CBD and into creating THC-based medications as well. This gives them the freedom to explore how a range of cannabinoid treatments may be used to as an option for difficult to treat conditions.

Story Source: The above story is based on materials provided by MEDICALMARIJUANAINC
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News